Uncategorized

EnGene’s shares crash on updated pivotal bladder cancer data

Published

3 hours ago

on

EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects.

The Canadian biotech’s shares {$ENGN} fell 80% Thursday morning after reporting …

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version